From discovery to the clinic

It is well known, especially for readers of this blog, that once biotech companies discover a new potential therapeutic, they take it through clinical trials in order to market the drug to actual patients. But how do biotechs come up with these clinical candidates, and how are potential drugs de-risked…

How do biotech companies raise capital?

What are some ways in which biotechs can raise money? Research and development is expensive, especially in the biotech realm. Cells, antibodies, animal models, infrastructure, etc. can lead to individual experiments costing thousands of dollars. So how do pre-revenue companies raise money to perform their experiments? How can they de-risk…

Smid-Cap Biotech Stock Catalysts

Biotwitter and the media are constantly sharing and discussing breaking biotech news: clinical trial outcomes, FDA decisions, and on and on. In turn, biotech stock valuations can change substantially very quickly. This is most pronounced in smaller, riskier companies with a single or small number of assets. So, what are…

Example mini-report: RTRX

For this week, I thought it would be valuable to share a mini-report I wrote to illustrate my thought process on the odds of success for an upcoming clinical trial. Here, I review Sparsentan from Retrophin ($RTRX), being investigated in a Phase 3 trial for the treatment of FSGS. I…

Starting Out

I will be sharing science-focused evaluations of clinical candidates and pipelines, as related to the business of biotech, but I feel the need to highlight a few things that I believe are super important to remember when investing in the biotech (or any) space. These are some important points about…